Cargando…

Glucocorticoid Receptor Antagonism Upregulates Somatostatin Receptor Subtype 2 Expression in ACTH-Producing Neuroendocrine Tumors: New Insight Based on the Selective Glucocorticoid Receptor Modulator Relacorilant

Somatostatin exhibits an inhibitory effect on pituitary hormone secretion, including inhibition of growth hormone and adrenocorticotropic hormone (ACTH), and it can have antisecretory and antitumor effects on neuroendocrine tumors (NETs) that express somatostatin receptors. Although the precise mech...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pivonello, Rosario, Munster, Pamela N., Terzolo, Massimo, Ferrigno, Rosario, Simeoli, Chiara, Puglisi, Soraya, Bali, Utsav, Moraitis, Andreas G.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Endocrinology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8764187/ https://www.ncbi.nlm.nih.gov/pubmed/35058882 http://dx.doi.org/10.3389/fendo.2021.793262

Ejemplares similares

THU035 Impact Of Surgery Or Medical Treatment With The Selective Glucocorticoid Receptor Modulator Relacorilant On Hypercoagulopathy In Patients With Cushing Syndrome
por: Simeoli, Chiara, et al.
Publicado: (2023)

Peripheral glucocorticoid receptor antagonism by relacorilant with modest HPA axis disinhibition
por: Viho, Eva M G, et al.
Publicado: (2022)

Relacorilant, a Selective Glucocorticoid Receptor Modulator, Induces Clinical Improvements in Patients With Cushing Syndrome: Results From A Prospective, Open-Label Phase 2 Study
por: Pivonello, Rosario, et al.
Publicado: (2021)

Corrigendum: Relacorilant, a Selective Glucocorticoid Receptor Modulator, Induces Clinical Improvements in Patients With Cushing Syndrome: Results From A Prospective, Open-Label Phase 2 Study
por: Pivonello, Rosario, et al.
Publicado: (2022)

SUN-463 Tumor Shrinkage with Preoperative Relacorilant Therapy in Two Patients with Cushing Disease Due to Pituitary Macroadenomas
por: Terzolo, Massimo, et al.
Publicado: (2019)

PMON165 Favorable Liver Safety Profile of the Selective Glucocorticoid Receptor Modulator Relacorilant in Healthy and Hepatically Impaired Adults and in Patients with Cushing Syndrome
por: Moraitis, Andreas, et al.
Publicado: (2022)

Relacorilant With Pembrolizumab: A Phase 1b, Open-Label Study of a Selective Glucocorticoid Receptor Modulator Combined With a Checkpoint Inhibitor for Patients With Adrenocortical Carcinoma With Excess Glucocorticoid Production
por: Habra, Mouhammed Amir, et al.
Publicado: (2021)

SUN-451 A Randomized-Withdrawal, Placebo-Controlled, Phase 3 Study to Assess the Efficacy and Safety of Selective Glucocorticoid Receptor Antagonist, Relacorilant, in Patients with Cushing Syndrome (GRACE Study)
por: Auchus, Richard, et al.
Publicado: (2019)

Overcoming Taxane Resistance: Preclinical and Phase 1 Studies of Relacorilant, a Selective Glucocorticoid Receptor Modulator, with Nab-Paclitaxel in Solid Tumors
por: Munster, Pamela N., et al.
Publicado: (2022)

GLUCOCORTICOID-INDUCED HYPERTENSION AND CARDIAC INJURY: EFFECTS OF MINERALOCORTICOID AND GLUCOCORTICOID RECEPTOR ANTAGONISM
por: HATTORI, TAKUYA, et al.
Publicado: (2013)

Glucocorticoid excess and COVID-19 disease
por: Guarnotta, Valentina, et al.
Publicado: (2020)

Proopiomelanocortin, glucocorticoid, and CRH receptor expression in human ACTH-secreting pituitary adenomas
por: Cassarino, Maria Francesca, et al.
Publicado: (2016)

Glucocorticoid receptor antagonism promotes apoptosis in solid tumor cells
por: Greenstein, Andrew E., et al.
Publicado: (2021)

MON-163 A Phase 3, Double-Blind, Randomized, Placebo-Controlled Study to Assess the Efficacy and Safety of a Selective Glucocorticoid Receptor Modulator, Relacorilant, in Patients with Autonomous Cortisol Secretion Due to Cortisol-Secreting Adrenal Adenoma(s)/Hyperplasia
por: Auchus, Richard Joseph, et al.
Publicado: (2020)

RF01 | PMON168 Hedgehog-Induced Somatostatin Receptor Expression is Inhibited by the Activation of the Glucocorticoid Receptor Signaling Pathway in Human Pituitary Adenoma Organoids
por: Zavros, Yana, et al.
Publicado: (2022)

COVID-19 and Cushing's syndrome: recommendations for a special population with endogenous glucocorticoid excess
por: Pivonello, Rosario, et al.
Publicado: (2020)

Familial Glucocorticoid Deficiency with a Point Mutation in the ACTH Receptor: A Case Report
por: Kim, Chan Jong, et al.
Publicado: (2009)

Antioxidant Treatment Induces Hyperactivation of the HPA Axis by Upregulating ACTH Receptor in the Adrenal and Downregulating Glucocorticoid Receptors in the Pituitary
por: Prevatto, Jessika P., et al.
Publicado: (2017)

Glucocorticoid receptor antagonism reverts docetaxel resistance in human prostate cancer
por: Kroon, Jan, et al.
Publicado: (2016)

Glucocorticoid Receptor Antagonism as a New “Remedy” for Insulin Resistance—Not There Yet!
por: Varlamov, Elena V, et al.
Publicado: (2021)

Role of Glucocorticoids and Glucocorticoid Receptors in Glaucoma Pathogenesis
por: Patel, Pinkal D., et al.
Publicado: (2023)

Glucocorticoid Receptor–Tethered Mineralocorticoid Receptors Increase Glucocorticoid-Induced Transcriptional Responses
por: Rivers, Caroline A, et al.
Publicado: (2019)

Analysis of BCLI, N363S and ER22/23EK Polymorphisms of the Glucocorticoid Receptor Gene in Adrenal Incidentalomas
por: Reimondo, Giuseppe, et al.
Publicado: (2016)

Role of mitochondrial glucocorticoid receptor in glucocorticoid-induced apoptosis
por: Sionov, Ronit Vogt, et al.
Publicado: (2006)

Susceptibility and characteristics of infections in patients with glucocorticoid excess or insufficiency: the ICARO tool
por: Minnetti, Marianna, et al.
Publicado: (2022)

One Hormone for Two Receptors: Exploring Glucocorticoid Actions Mediated by the Glucocorticoid and Mineralocorticoid Receptors
por: Petrillo, Maria G, et al.
Publicado: (2021)

Mifepristone Plasma Level and Glucocorticoid Receptor Antagonism Associated With Response in Patients With Psychotic Depression
por: Block, Thaddeus, et al.
Publicado: (2017)

Mitigation of metabolic dyshomeostasis by glucocorticoid-receptor antagonism: Insights from animal and human studies
por: Madhavan, Aishwariya, et al.
Publicado: (2020)

Interaction of glucocorticoids with macrophages. Identification of glucocorticoid receptors in monocytes and macrophages
Publicado: (1978)

Association of Glucocorticoid Insensitivity with Increased Expression of Glucocorticoid Receptor β
por: Leung, Donald Y.M., et al.
Publicado: (1997)

Glucocorticoid Receptor and Adipocyte Biology
por: Lee, Rebecca A., et al.
Publicado: (2018)

Mitochondrial Glucocorticoid Receptors and Their Actions
por: Kokkinopoulou, Ioanna, et al.
Publicado: (2021)

Glucocorticoid Receptor Signaling in Diabetes
por: Kokkinopoulou, Ioanna, et al.
Publicado: (2021)

Somatostatin and Somatostatin Receptors: From Signaling to Clinical Applications in Neuroendocrine Neoplasms
por: del Olmo-Garcia, Maria Isabel, et al.
Publicado: (2021)

Glucocorticoid Receptor Antagonist Administration Prevents Adrenal Gland Atrophy in an ACTH-Independent Cushing's Syndrome Rat Model
por: Yasuda, Atsushi, et al.
Publicado: (2019)

Glucocorticoid-dependent transcription in skin requires epidermal expression of the glucocorticoid receptor and is modulated by the mineralocorticoid receptor
por: Sevilla, Lisa M., et al.
Publicado: (2020)

Antagonizing urotensin receptor is a novel therapeutic strategy for glucocorticoid‐induced skeletal muscle atrophy
por: Yin, Lin, et al.
Publicado: (2022)

Glucocorticoid Receptor Transactivation Is Required for Glucocorticoid-Induced Ocular Hypertension and Glaucoma
por: Patel, Gaurang C., et al.
Publicado: (2019)

Glucocorticoid Resistance: Interference between the Glucocorticoid Receptor and the MAPK Signalling Pathways
por: Sevilla, Lisa M., et al.
Publicado: (2021)

Epigenetic regulation of somatostatin and somatostatin receptors in neuroendocrine tumors and other types of cancer
por: Klomp, M.J., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_e9bsmtue4stv6rvikric0hi5ok